Previous 10 | Next 10 |
Conference Call Scheduled for Monday, February 24, 2020 at 4:30 p.m. ET Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection ...
Revance Therapeutics (NASDAQ: RVNC ) prices its private $250M (from $200M) offering of 1.75% convertible senior notes due 2027 at par. Initial buyers have a 13-day option to purchase an additional $37.5M of the notes. More news on: Revance Therapeutics, Inc., Healthcare stocks news, Stoc...
Revance Therapeutics, Inc. (“Revance”) (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the pricing of $250.0 million aggregate principal amount of 1.75% convertible senio...
Revance Therapeutics, Inc. (“Revance”) (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that it intends to offer, subject to market conditions and other factor...
Shares of Allergan (NYSE: AGN) received a slight bump on Monday morning in response to a fourth-quarter earnings report that exceeded expectations on the top and bottom lines. Shares of AbbVie (NYSE: ABBV) , a larger drugmaker with plans to buy Allergan in the first quarter...
Revance Therapeutics (NASDAQ: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (“DAXI”), today announced the U.S. Food and Drug Administration’s...
A new alternative to Allergan 's (NYSE: AGN) blockbuster aesthetics treatment Botox may be available by the end of 2020. On Thursday, Revance Therapeutics (NASDAQ: RVNC) announced the Food and Drug Administration (FDA) accepted its application for approval of DAXI (daxibotulinum...
Revance Therapeutics (NASDAQ: RVNC ) has filed a marketing application in the U.S. seeking approval of DAXI (daxibotulinumtoxinA for injection) for the treatment of moderate-to-severe glabellar (frown) lines. The agency's action date is November 25. More news on: Revance Therapeutics, In...
- Prescription Drug User Fee Act (PDUFA) target action date of November 25, 2020 - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA f...
The following slide deck was published by Revance Therapeutics, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding confe...
– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract examining the influence of DAXXIFY’s formulation on clinical performance ...
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during T...